|
|||||||||||||||||||||||
 |
Chelation Study 7 |
|
|
|||||||||||||||||||||||||||
|
What is EDTA Chelation Therapy?
Its Value & Effects Chelation Therapy is a safe, effective and relatively inexpensive treatment to restore blood flow in victims of atherosclerosis without surgery.
Chelation Therapy involves the intravenous infusion of a prescription
medicine called Ethylene Diamine Tetra-Acetic Acid (EDTA), plus vitamins
and minerals at therapeutic dosages.
EDTA helps prevent the production of harmful 'Free Radicals' through elimination. Arterial disease is responsible for strokes, heart attacks, poor circulation and memory loss. Detoxamin - EDTA chelationAn EDTA chelation therapy medical
breakthrough… For years EDTA chelation therapy has been instrumental in literally saving the lives of people across the globe. The results of this therapy have given patients a new lease on life. EDTA chelation therapy works by removing the toxic heavy metals from damaged hearts and heart valves as well as from hidden stores within blood vessels, kidneys, and more. You see, by removing the circulatory heavy metal toxins, EDTA enhances cardiovascular blood flow and function. As highly recommended as this therapy has been
in the past, the only effective way to receive the therapy has been
intravenously. This requires sitting in a doctor's office while the EDTA
is slowly introduced into your bloodstream, via IV, over a 3-4 hour
period. The time, the expense, the invasiveness of the needle and the
overall inconvenience has made this therapy out of reach to most people,
until now. We are so confident that you will experience better health once you start using Detoxamin; I understand how important this information is to you as I see patients every day with both chronic and acute health problems. From heart disease, diabetes, high blood pressure, cardiovascular diseases, chronic fatigue, cancer to prostate issues and so many more diseases prominent today, it is apparent that each have one thing in common. They are all linked to our increasing exposure to heavy metals in our environment. In my clinic, Tustin Longevity Center (TLC), I have found heavy metals in the vast majority of my patients; this is without the patients even knowing that they are carriers of heavy metals in their bodies. This is why for years I have been administering IV EDTA chelation and am fully aware of the problems associated with it. For years I have been looking for a method of EDTA chelation that offered more affordability, more convenience and safety, without losing any effectiveness. I tried Oral EDTA and other methods, and none would compare with the results I experienced with IV EDTA chelation - until I started to use Detoxamin. Clinically, my patient-population experiences demonstrate improved energy, mood and mental function as these oxidizing metals are reduced with Detoxamin. Detoxamin is the 21st century antioxidant key (along with a healthy lifestyle) needed to survive living in our toxic world. As a medical authority on Detoxamin, I truly believe Detoxamin is one of the most significant means to improve patients' overall health that I've experienced in my 30 years of practice. And as of now, I have treated more than 600 patients with Detoxamin. Why are you looking into chelation therapy? We find that the three most common reasons are:
Whatever your reason is for visiting us today, we hope we give you
what you are looking for. The benefits of using Detoxamin are astounding:
Medically equivalent to IV EDTA chelation. This is another huge aspect of why Detoxamin is so popular throughout the world. People for years have been frustrated with the inconvenient delivery of EDTA into the body. Now that this method is available, most people prefer it and in most cases the results are even better than with the IV method. For every three Detoxamin, you receive about the same dosage you would get in one IV treatment, but with a much safer and more convenient delivery method.
Drug Treatment for Iron Overload Deferiprone should be used in patients with thalassaemia and other patients with iron overload, who cannot receive effective or sufficient deferoxamine therapy. This was the recommendation issued following the 10th International Conference on Oral Chelation, March 22-26, 2000, Limassol, Cyprus.1 At least one third of patients with thalassaemia in countries in which deferoxamine is available have serum ferritin in excess of 2500 mg/L and in general a higher morbidity and mortality rate than those with a target serum ferritin below 2500 mg/L. This reflects the low compliance with subcutaneous deferoxamine. Whereas, more than 80% of patients with thalassaemia are born in Asia and Middle Eastern countries, only 10% of those transfused are adequately chelated. For these parts of the world deferoxamine is too costly to offer patients. The remainder are at risk of irreversible organ damage and death resulting from iron overload. Deferiprone in these countries could be supplied at an eighth of the price of deferoxamine. More than 6000 patients in 40 countries have received deferiprone since 1986.1,2 In India, where deferiprone has been a registered drug since 1994, there are more patients taking deferiprone than deferoxamine. Deferiprone has also been registered in Europe in 1999, following the recommendation by the European Community authorities that its use be restricted to patients who cannot tolerate deferoxamine and that patients on the drug be closely monitored for toxicity. Iron excretion in response to deferiprone appears to depend on the iron load and rate of iron loading of patients, the dose, frequency of administration, and metabolism of the drug.1-3 In about 70% of patients with thalassaemia treated with deferiprone (75-120 mg/kg/day) for more than 2 years, serum ferritin decreased and remained below 2500 mg/L.1 In the 30% of patients who were treated with a dose of 75 mg/kg/day or less and who failed to reach negative iron balance or experienced toxicity with deferiprone or deferoxamine, a combination of these two drugs appears to be more effective and less toxic than using either drug alone. No new toxic side effects of deferiprone have been identified and all those known are reversible, controlable, and manageable. Agranulocytosis, which is the most serious, affects less than 0.6% of patients on the drug and is satisfactorily monitored with weekly blood counts. Joint and musculoskeletal pains affect up to 15%, gastrointestinal complaints up to 10%, and zinc deficiency up to 1% of the treated patients. Contrary to the claim that deferiprone initiates or increases the progression of liver fibrosis,4,5 no other investigators have substantiated these findings nor have they observed significant differences by comparison to patients receiving deferoxamine.1 This observation was made in groups of patients who had been taking deferiprone daily for over 10 years in India and Switzerland.1,3 New oral chelators, if successful, will certainly not be available at least in the next 5 years. New protocols aimed at improving deferiprone therapy are also being developed. Deferiprone remains the drug of choice for those patients who cannot afford the high cost of deferoxamine, cannot comply with its subcutaneous infusion, or cannot overcome its toxicity. The prognosis of patients taking deferiprone is much better than that of patients experiencing iron overload toxicity because of lack of chelation therapy or ineffective or insufficient chelation therapy with deferoxamine. *G J Kontoghiorghes, M B Agarwal, R W Grady, A Kolnagou, J J Marx *Postgraduate Research Institute, CY-3021 Limassol, Cyprus; Department of Haematology, LTMG Hospital and LTM Medical College, Mumbai, India; Cornell University Medical Centre, New York, USA; Thalassaemia Unit, Paphos General Hospital, Paphos, Cyprus; and Department of Internal Medicine, University Medical Centre, Utrecht, The Netherlands REFERENCES: 1 10th International Conference on Oral Chelation in the Treatment of Thalassaemia and other Diseases (ICOC), Limassol, Cyprus, March 22-26, 2000, 1-56. 2 Oral chelation in the treatment of thalassaemia and other diseases [suppl]. Kontoghiorghes GJ, ed. Drugs of Today 1992; 28 (A): 1-187. 3 Tondury P, Zimmerman A, Nielsen P, Hirt A. Liver iron fibrosis during long-term treatment with deferiprone in Swiss thalssaemic patients. Br J Haematol 1998; 101: 413-15. 4 Olivieri NF, Brittenham GM, Mclaren C, et al. Long term safety and effectiveness of iron chelation therapy with deferiprone for thalassaemia major. N Engl J Med 1998; 339: 417-23. 5 Kowdly KV, Kaplan MM. Iron chelation therapy with oral deferiprone -- toxicity or lack of efficacy. N Engl J Med 1998; 339: 468-69. Lancet 2000; 356: 428 - 434
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||
